BridgeBio Pharma CEO Neil Kumar sells $690,847 in shares
BridgeBio Pharma CEO Neil Kumar offloaded a total of 10,000 shares of the company's common stock on September 17, 2026, through a pre-approved Rule 10b5-1 sales plan. The transactions were carried out between May 13, 2026, and September 17, 2026, and generated $690,847 in proceeds. The shares were sold within the range of $69.0136 to $69.5696 per share, with an 8,721 share allocation at an average price of $69.0136 and 1,279 shares at an average price of $69.5696.
Kumar, who holds a majority indirect beneficial ownership in the company, also maintains a significant stake through various trusts and a granting-related trust (GRAT). Despite recent stock performance indicating slight overvaluation, major brokerage firms such as Canaccord and H.C. Wainwright have maintained a Buy rating for BridgeBio Pharma, supporting its potential for growth.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
